Nipodur (Ranitidine Hydrochloride)

Ranitidine Hydrochloride, the active ingredient in Nipodur, is a H2 receptor antagonist presented as an oral dosage form for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, erosive esophagitis and Zollinger‑Ellison syndrome in adult patients.

GNH USA supplies Nipodur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and is manufactured under GMP conditions.

Nipodur (ranitidine) is employed in the management of acid‑related gastrointestinal disorders.

- Gastro‑oesophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of the esophageal lining. - Peptic ulcer disease: facilitates ulcer healing by lowering gastric acidity. - Erosive esophagitis: protects damaged esophageal tissue and supports mucosal recovery. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumours.

Like other H2 antagonists, ranitidine may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness: transient sensation of light‑headedness. - Constipation: occasional reduced bowel movements. - Diarrhoea: loose stools, usually self‑limiting. - Nausea: mild stomach upset. - Rash: mild skin erythema or itching.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Liver dysfunction: elevated transaminases or hepatitis. - Thrombocytopenia: reduced platelet count, may cause bleeding. - Cardiac arrhythmia: irregular heart rhythm, especially in predisposed patients. - Neutropenia: low neutrophil count, increasing infection risk. - Interstitial nephritis: inflammation of kidney interstitium, may impair renal function.

When prescribing Nipodur, several safety considerations should be reviewed.

- Renal function: assess and adjust dose in patients with severe impairment. - Liver function: monitor hepatic enzymes in individuals with liver disease. - Hypersensitivity: discontinue immediately if allergic reaction occurs. - Pregnancy: use only if the potential benefit outweighs the potential risk to the fetus. - Elderly: start with the lowest effective dose and monitor for adverse effects. - Store at room temperature: keep in the original container, protect from moisture and heat.

Ranitidine can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole: markedly reduced absorption; separate administration by at least 2 hours. - Atazanavir: decreased plasma levels; avoid concomitant use. - Itraconazole: reduced efficacy; avoid co‑administration. - Iron salts: impaired iron absorption; separate dosing. - Sucralfate: decreased effectiveness; avoid together.

Moderate Interactions (Monitor Closely): - Warfarin: possible increased anticoagulant effect; monitor INR. - Theophylline: increased clearance; observe serum levels. - Cimetidine (if used): additive H2 blockade; watch for excess acid suppression. - Digoxin: slight increase in serum concentration; monitor for toxicity. - Methotrexate: reduced renal clearance; monitor renal function and drug levels.